A team at the University of Alabama at Birmingham argues that cardiovascular aging is best understood not as the slow accumulation of plaque and scar tissue, but as the progressive breakdown of a mitochondrial network that spans heart muscle, endothelium and microvasculature. Their case rests on three linked failures: energy reserve contracts even while resting ATP looks normal; quality control falters as cristae architecture, cardiolipin, fission-fusion balance and mitophagy degrade; and signaling turns maladaptive when mitochondrial DNA escapes into the cytosol and triggers cGAS-STING driven sterile inflammation. The authors propose a composite “Mitochondrial Functional Age” panel to measure this state in living people, and they argue the earliest and most tractable failure point is the coronary microvascular endothelium rather than the cardiomyocyte.
For fifty years, cardiology has treated the aging heart mostly as a structural object. Arteries narrow, walls thicken, valves calcify, muscle scars. Mitochondria entered the story late, and usually as a footnote about oxidative stress. A review out of the University of Alabama at Birmingham argues that the footnote should be the headline.
The central claim is a shift in unit of analysis. Mitochondria in heart tissue are not a bag of independent power plants whose output you can average. They form a physically connected, constantly reshaping network that has to match energy supply to demand on a beat-to-beat basis while simultaneously buffering calcium, controlling redox tone, and deciding which damaged components to recycle. Aging, on this view, does not primarily reduce how much energy the network makes at rest. It reduces how much the network can surge when challenged, and how reliably it cleans up after itself.
That distinction matters clinically because it explains a long-standing puzzle. Older hearts frequently show normal resting energetics and a normal ejection fraction, yet fail conspicuously under load. The reserve is gone before the baseline moves. The authors point to spare respiratory capacity, the gap between maximum and resting oxygen consumption, as the metric that actually tracks functional decline, and they note that measuring resting ATP is close to useless for detecting it.
The second argument is about location. Most attention has gone to the cardiomyocyte, but the review places the earliest failure in the endothelial cells lining the coronary microcirculation. These cells do not use mitochondria mainly for bulk energy production. They use them as signaling nodes that set nitric oxide availability and inflammatory tone. When their mitochondria drift toward higher oxidant output, nitric oxide synthase begins producing superoxide instead of nitric oxide, the glycalyx lining thins, blood flow reserve falls, and the muscle downstream inherits an oxygen supply ceiling it did not create. This is a plausible mechanistic route to heart failure with preserved ejection fraction, a condition that has resisted almost every drug thrown at it.
The third argument is about inflammation. When mitochondrial membranes are compromised, mitochondrial DNA leaks into the cytosol, where innate immune sensors read its bacterial-like features as an infection. The result is chronic sterile inflammation that drives fibrosis and vascular stiffening, a self-reinforcing loop the authors call mitoinflammation.
Underneath all of this sits a measurement problem, and the authors’ proposed fix is the part most likely to outlast the rest of the paper. They want a composite “mitochondrial age” built from four readouts: how quickly phosphocreatine recovers in muscle after brief exercise, how much spare respiratory capacity circulating immune cells have, what fluorescence lifetime imaging says about cellular redox state, and how much cell-free mitochondrial DNA is in the blood. All four exist already. None is standardized, and the review is blunt that circadian timing and sample handling change the answers enough to wreck comparability between sites.
The therapeutic implication is a break from the antioxidant era. Vitamin E and beta-carotene trials failed, the authors argue, because blanket ROS suppression also erases the redox signaling cells need. What replaces it is narrower: stabilize the inner membrane, restore mitophagy flux, raise the permeability transition threshold, and judge success by stress-tested reserve rather than resting biomarkers.
Insights
Nothing here is a new intervention. It is a case for choosing interventions by mechanism and judging them by stress-tested function. Four items have human data worth quantifying.
MitoQ, a mitochondria-targeted antioxidant, is the strongest signal. In a 6-week crossover trial in 20 healthy adults aged 60 to 79, brachial artery flow-mediated dilation was 42 percent higher on 20 mg/day versus placebo. In absolute terms that is a 1.48 percentage point difference (Cohen’s d = 0.64, a moderate effect). To make that concrete, a moderate effect means roughly a two in three chance that a randomly chosen treated person improved more than a randomly chosen untreated person. Population data link each 1 percentage point of flow-mediated dilation to 4 to 13 percent lower cardiovascular event risk, so the observed change maps to roughly a 6 to 19 percent relative risk reduction if the surrogate translates, which is unproven.
Urolithin A improved leg strength by about 10 to 12 percent versus placebo over 4 months, but missed its primary endpoints in both major trials. Nicotinamide riboside plus exercise did not beat exercise alone on blood pressure.
Practical translation: exercise remains the only intervention here with reserve-capacity effects large enough to be reliable. Supplements target real mechanisms with modest, surrogate-level evidence.
Context and Source
- Open Access Paper: Understanding cardiovascular aging as a disorder of mitochondrial network
- Institution: Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, Alabama, USA
- Country: United States
-
Journal: The Journal of Cardiovascular Aging (OAE Publishing Inc.), 2026.
Impact evaluation: The impact score of this journal is 4.4 (Journal Impact Factor, JCR 2025), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Low impact journal.